Kimberly Gates, APRN
Family · North Little Rock, ARNPI 1346749504
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,805 of the $30,651 with a category attached, or 90.7%. AbbVie accounts for 94.2% of it on its own, with 24 other manufacturers making up the rest. Among family clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $204.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$29K
- GSK$271
- Abbott$266
- Pfizer$170
- Otsuka America Pharmaceutical, Inc.$147
- Amgen$132
- plus $788 from 19 others
What the payments were for
- Speaking & faculty fees$27,80591%
- Travel & lodging$280%
- Food & beverage$2,8009%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $28,876 |
| GSK | 18 | $271 |
| Abbott | 13 | $266 |
| Pfizer | 12 | $170 |
| Otsuka America Pharmaceutical, Inc. | 7 | $147 |
| Amgen | 10 | $132 |
| Novo Nordisk | 8 | $126 |
| Esperion Therapeutics, Inc. | 1 | $106 |
| Johnson & Johnson | 4 | $96 |
| Lilly USA, LLC | 4 | $56 |
| Lundbeck LLC | 2 | $53 |
| Astellas Pharma US Inc | 3 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| Ironshore Pharmaceuticals Inc. | 2 | $41 |
| Corium, LLC | 3 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,651 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,403 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $527 |
| Atorvastatin Calcium | 44 | $468 |
| Buspirone Hcl | 16 | $260 |
| Metoprolol Succinate | 11 | $251 |
| Montelukast Sodium | 24 | $209 |
| Trazodone Hcl | 33 | $175 |
| Fluoxetine Hcl | 12 | $126 |
| Escitalopram Oxalate | 14 | $104 |
| Lisinopril | 25 | $61 |
| Levothyroxine Sodium | 12 | $46 |
| Zolpidem Tartrate | 11 | $30 |
| Tizanidine Hcl | 11 | $25 |
| Simvastatin | 11 | $10 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $271 | $9,40315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.
Other family in North Little Rock
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
- Shelby CochranFayetteville$23K
- Michael StirlingLittle Rock$23K
- Jessica MatthewsJonesboro$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.